Nivolumab Causing a Polymyalgia Rheumatica in a Patient With a Squamous Non–Small Cell Lung Cancer
Autor: | Sophie Fedrizzi, Cyril Guillaumé, Jeannick Madelaine, Joachim Alexandre, Marion Sassier, Florian Lecaignec, Léa Hamel-Sénécal, Basile Chrétien, Marjorie Bernier, Nathalie Leon, Xavier Humbert |
---|---|
Rok vydání: | 2017 |
Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Immunology Arthritis Gastroenterology Polymyalgia rheumatica 03 medical and health sciences 0302 clinical medicine Prednisone Internal medicine medicine Immunology and Allergy Endocrine system Adverse effect 030203 arthritis & rheumatology Pharmacology biology business.industry Immunotherapy medicine.disease 030220 oncology & carcinogenesis biology.protein Nivolumab Antibody business medicine.drug |
Zdroj: | Journal of Immunotherapy. 40:129-131 |
ISSN: | 1524-9557 |
Popis: | The anti-programmed cell-death-1 antibody, nivolumab, has been recently approved for the treatment of advanced non-small cell lung cancer. Although, today, immune-related adverse effects such as dermatologic, digestive, hepatic, and endocrine toxicities are well-known with immune checkpoint inhibitors, rheumatic diseases are less well described. Herein, we report the case of a patient without a history of arthritis who developed polymyalgia rheumatica after 13 cycles of nivolumab used for the treatment of advanced non-small cell lung cancer. Laboratory evidence of inflammatory syndrome, articular echography, and clinical presentation with classical symptoms and also distal manifestations were suggestive of this chronic inflammatory disorder. Because of a relevant pain, clinicians were forced to suspend immunotherapy. Nevertheless, due to glucocorticoid therapy, the patient's symptoms have decreased progressively. Moreover, nivolumab was reintroduced 8 weeks later, whereas prednisone (10 mg) was continued, without any recurrence symptoms. To conclude, our case suggests that polymyalgia rheumatica might be a very disabling anti-programmed cell-death-1 immune-related adverse effect. |
Databáze: | OpenAIRE |
Externí odkaz: |